Edition:
United States

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

25.35USD
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
$25.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
731,018
52-wk High
$26.45
52-wk Low
$7.20

Chart for

About

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $4,073.21
Shares Outstanding(Mil.): 167.35
Dividend: --
Yield (%): --

Financials

  IMMU.OQ Industry Sector
P/E (TTM): -- 235.76 33.88
EPS (TTM): -1.53 -- --
ROI: -164.45 -5.45 13.21
ROE: -- -6.94 15.18

BRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA

* IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION

May 21 2018

BRIEF-Immunomedics Announces Promising Data Of Sacituzumab Govitecan In Estrogen Receptor-Positive Metastatic Breast Cancer

* IMMUNOMEDICS ANNOUNCES PROMISING DATA OF SACITUZUMAB GOVITECAN IN ESTROGEN RECEPTOR-POSITIVE METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:

May 16 2018

BRIEF-Immunomedics Reports Q3 Loss Per Share $0.21

* IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Immunomedics Q2 Loss Per Share $0.02

* IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE

Feb 08 2018

BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer

* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER

Jan 11 2018

BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln

* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION

Jan 08 2018

Competitors

Earnings vs. Estimates